Cost-effectiveness of Chemotherapy for Pancreatic Cancer in China
Author Information
Author(s): Xiang Zuojuan, Ma Ling, Li Zhengxiong, Fu Yingzhou, Pan Yong
Primary Institution: The Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, Hunan Cancer Hospital, Changsha, China
Hypothesis
What is the cost-effectiveness of NALIRIFOX compared to FOLFIRINOX and GEMNABP for treating metastatic pancreatic cancer in China?
Conclusion
GEMNABP is the most cost-effective treatment option among the three chemotherapy regimens for metastatic pancreatic cancer under current market conditions.
Supporting Evidence
- GEMNABP was associated with the lowest life-years and quality-adjusted life years.
- NALIRIFOX yielded the highest life-years and quality-adjusted life years but was not cost-effective.
- The cost-effectiveness of NALIRIFOX improves significantly if the price of liposomal irinotecan is reduced.
Takeaway
This study looked at how much different cancer treatments cost and how well they work. It found that one treatment is cheaper and better than the others.
Methodology
A partitioned survival model was used to evaluate the cost-effectiveness of three chemotherapy regimens from the perspective of the Chinese healthcare system.
Potential Biases
Potential bias due to the reliance on previously published data and the lack of direct head-to-head comparisons.
Limitations
The study's model was based on indirect comparisons and may not fully reflect the effectiveness and safety of treatments in the Chinese population.
Participant Demographics
Patients were adults aged 18 years or older with metastatic pancreatic ductal adenocarcinoma.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website